Rick Anderson

Rick joined PTV as a Managing Director in 2008. Rick currently sits on the boards of PTV portfolio companies Apollo Endosurgery, Corventis, Intersect ENT, and Tryton Medical, and he serves as Chairman of the Board for Cardiva Medical. Rick was also a Director at Cameron Health prior to its acquisition by Boston Scientific in June 2012 and Chairman of the Board for IDev Technologies prior to its acquisition by Abbott in August 2013. Prior to joining PTV, Rick was Company Group Chairman, Johnson & Johnson, and Worldwide Franchise Chairman, Cordis Corporation. Rick also served as President of Cordis Corporation and was previously Worldwide Franchise Vice President of Centocor, Inc., which merged with Johnson & Johnson in 1999. Rick was a key architect behind the launch of the world’s first drug-eluting stent, the CYPHER® Sirolimus-eluting Coronary Stent. This breakthrough innovation for the treatment of restenosis (reblockage) has been used to treat more than three million patients worldwide. Before joining Johnson & Johnson, Rick served in senior leadership positions with other international healthcare and medical device companies. At Racal HealthCare, Inc., he was Vice President, Global Marketing and prior to that, he spent a decade with Boehringer Mannheim Pharmaceuticals and Allergan Pharmaceuticals in various U.S. and global sales, sales management, and marketing management roles. Rick holds a B.B.A. in Marketing from Mississippi State University. He served five years in the U.S. Army where he obtained the rank of captain. Rick is a member of the Economic Advisory Board of Mississippi State University, a consultant member of the Society for Cardiovascular Angiography and Interventions, and he has worked within the industry to shape global education of interventional specialties. He participates in the AdvaMed Venture Capital Advisory Council and the Dartmouth Device Development (3D) Symposium Executive Committee, and he is a Director for the Heart Rhythm Society (HRS) Consulting Services and a member of the Accelerated Innovation Program Working Group for the National Heart Lung and Blood Institute (NHLBI).